Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

NCT06788938 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT06788938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tarlatamab in Advanced DLL3-Expressing Tumors Including Neuroendocrine Neoplasms
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 21, 2025
Completion date
April 24, 2029
Enrollment
29 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced tumors, dll3-expressing tumors